Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | N35N9 | — |
received only the adjuvant portion of Shingrix as a second dose; received only the adjuvant portion of Shingrix as a second dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number N35N9, expiry date 15-NOV-2026) for prophylaxis. Previously administered products included Shingrix (received 1st dose on an unknown date). On 13-JAN-2025, the patient received the 2nd dose of Shingrix. On 13-JAN-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: received only the adjuvant portion of Shingrix as a second dose) and inappropriate dose of vaccine administered (Verbatim: received only the adjuvant portion of Shingrix as a second dose). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional Information: GSK receipt date: 06-FEB-2025 The medical assistant reported that they accidentally administered only the adjuvant portion of Shingrix to a patient which led to, inappropriate preparation of medication and inappropriate dose of vaccine administered. The patient already had the first dose of Shingrix, but for the second dose she only got the adjuvant portion of Shingrix. The reporter had a question what could potentially happened to the patient or any adverse event that they should look for.